Trimel Pharmaceuticals Corporation
TSX : TRL

Trimel Pharmaceuticals Corporation

November 27, 2013 07:30 ET

Trimel Pharmaceuticals Corporation Announces Appointment of New Director

TORONTO, ONTARIO--(Marketwired - Nov. 27, 2013) - Trimel Pharmaceuticals Corporation (TSX:TRL) today announced the appointment of Mr. Matthew Pfeffer to its Board of Directors.

Mr. Pfeffer currently serves as the Corporate Vice President and Chief Financial Officer of MannKind Corporation, a United States based biopharmaceutical company with a market capitalization of approximately US$1.8 billion focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. In addition, Mr. Pfeffer has gained considerable experience throughout his career in financial management roles at a number of other public companies in the pharmaceutical industry. Mr. Pfeffer has also served on the boards and advisory committees of the Biotechnology Industry Organization and the American Institute of Certified Public Accountants.

"We are pleased to welcome Mr. Pfeffer to Trimel's Board of Directors", commented Bruce D. Brydon, Chairman of the Board. "Mr. Pfeffer will provide Trimel's Board with strengthened insight as it pertains to the United States marketplace. Mr. Pfeffer's experience in finance, investor relations and combination drug device product development represents a significant asset to Trimel as we move forward in the building of our business."

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. A New Drug Application for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been filed with the United States Food and Drug Administration for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.

Contact Information